Retention and Survival Rate of Etanercept in Psoriasis over 15 years and Patient Outcomes During the COVID-19 Pandemic: The Real-world Experience of a Single Center

Overview

Journal Dermatol Ther

Specialty Dermatology

Date 2020 Dec 4

PMID 33274541

Citations 7

Authors

Nahide Onsun

Begum Gunes

Aysegul Yabaci

Affiliations

Soon will be listed here.

Abstract

There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.

Citing Articles

Etanercept alleviates psoriasis by reducing the Th17/Treg ratio and promoting M2 polarization of macrophages.

Li X, Jiang M, Chen X, Sun W Immun Inflamm Dis. 2022; 10(12):e734.

PMID: 36444619 PMC: 9639465. DOI: 10.1002/iid3.734.

A Review of Potential Therapeutic Strategies for COVID-19.

Meng J, Li R, Zhang Z, Wang J, Huang Q, Nie D Viruses. 2022; 14(11).

PMID: 36366444 PMC: 9696587. DOI: 10.3390/v14112346.

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis.

Piragine E, Petri D, Martelli A, Janowska A, Dini V, Romanelli M J Clin Med. 2022; 11(6).

PMID: 35329831 PMC: 8953825. DOI: 10.3390/jcm11061506.

A Peek into Pandora's Box: COVID-19 and Neurodegeneration.

Chandra A, Johri A Brain Sci. 2022; 12(2).

PMID: 35203953 PMC: 8870638. DOI: 10.3390/brainsci12020190.

The Contributing Factors of Delayed-Onset Post-traumatic Stress Disorder Symptoms: A Nested Case-Control Study Conducted After the 2008 Wenchuan Earthquake.

Yang Y, Zeng W, Lu B, Wen J Front Public Health. 2022; 9:682714.

PMID: 35004555 PMC: 8739781. DOI: 10.3389/fpubh.2021.682714.

References

Lie E, Kristensen L, Forsblad-dElia H, Zverkova-Sandstrom T, Askling J, Jacobsson L . The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015; 74(6):970-8. DOI: 10.1136/annrheumdis-2014-206616. View

van Lumig P, Driessen R, Kievit W, Boezeman J, van de Kerkhof P, de Jong E . Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol. 2012; 68(1):57-63. DOI: 10.1016/j.jaad.2012.05.040. View

Gottlieb A, Matheson R, Lowe N, Krueger G, Kang S, Goffe B . A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139(12):1627-32. DOI: 10.1001/archderm.139.12.1627. View

Papp K, Tyring S, Lahfa M, Prinz J, Griffiths C, Nakanishi A . A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005; 152(6):1304-12. DOI: 10.1111/j.1365-2133.2005.06688.x. View

Minozzi S, Bonovas S, Lytras T, Pecoraro V, Gonzalez-Lorenzo M, Bastiampillai A . Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016; 15(sup1):11-34. DOI: 10.1080/14740338.2016.1240783. View

Reich K, Burden A, Eaton J, Hawkins N . Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2011; 166(1):179-88. DOI: 10.1111/j.1365-2133.2011.10583.x. View

Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo R . Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. Joint Bone Spine. 2014; 81(4):352-9. DOI: 10.1016/j.jbspin.2014.02.014. View

Heiberg M, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P . The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008; 59(2):234-40. DOI: 10.1002/art.23333. View

Bissonnette R . Etanercept for the treatment of psoriasis. Skin Therapy Lett. 2006; 11(1):1-4. View

10.

Menting S, Sitaram A, Bonnerjee-van der Stok H, de Rie M, Hooft L, Spuls P . Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014; 171(4):875-83. DOI: 10.1111/bjd.13001. View

11.

Gniadecki R, Kragballe K, Dam T, Skov L . Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011; 164(5):1091-6. DOI: 10.1111/j.1365-2133.2011.10213.x. View

12.

Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F . Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013; 169(3):666-72. DOI: 10.1111/bjd.12422. View

13.

Goffe B, Cather J . Etanercept: An overview. J Am Acad Dermatol. 2003; 49(2 Suppl):S105-11. DOI: 10.1016/mjd.2003.554. View

14.

Jimenez-Puya R, Gomez-Garcia F, Amorrich-Campos V, Moreno-Gimenez J . Etanercept: efficacy and safety. J Eur Acad Dermatol Venereol. 2009; 23(4):402-5. DOI: 10.1111/j.1468-3083.2008.03063.x. View

15.

Yousaf A, Gayam S, Feldman S, Zinn Z, Kolodney M . Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J Am Acad Dermatol. 2020; 84(1):70-75. PMC: 7484805. DOI: 10.1016/j.jaad.2020.09.009. View

16.

van Lumig P, Driessen R, Boezeman J, van de Kerkhof P, de Jong E . Long-term efficacy of etanercept for psoriasis in daily practice. Br J Dermatol. 2011; 166(2):445-7. DOI: 10.1111/j.1365-2133.2011.10584.x. View

17.

Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant M, Charland K . Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data. Clin Rheumatol. 2018; 37(9):2351-2360. DOI: 10.1007/s10067-018-4141-z. View

18.

Gniadecki R, Bang B, Bryld L, Iversen L, Lasthein S, Skov L . Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2014; 172(1):244-52. DOI: 10.1111/bjd.13343. View

19.

Arnold T, Schaarschmidt M, Herr R, Fischer J, Goerdt S, Peitsch W . Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016; 14(11):1089-1099. DOI: 10.1111/ddg.13152. View

20.

Fernandez-Torres R, Paradela S, Fonseca E . Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice. Value Health. 2015; 18(8):1158-61. DOI: 10.1016/j.jval.2015.07.010. View